Understanding Tertiary Lymphoid Structures in Type 1 Diabetes

Type 1 diabetes (T1D) is a chronic autoimmune condition characterized by the selective destruction of insulin-producing beta cells within the pancreatic islets. While the autoimmune attack is known to be driven by autoreactive T cells and B cells, the precise microanatomical organization of the immune response within the target organ has emerged as a critical area of investigation. Over the past decade, the identification of tertiary lymphoid structures (TLS) in the pancreata of individuals with T1D has reshaped our understanding of how local immune activation is sustained and amplified. These ectopic immune aggregates are not passive bystanders but active hubs that orchestrate and perpetuate the autoimmune process. Understanding TLS biology is rapidly becoming a cornerstone of T1D research, offering potential targets for interventions that could halt disease progression and even restore tolerance.

What Are Tertiary Lymphoid Structures?

Tertiary lymphoid structures are organized accumulations of lymphocytes, antigen-presenting cells, and stromal cells that develop in non-lymphoid tissues under conditions of chronic inflammation, infection, or autoimmunity. Unlike secondary lymphoid organs such as lymph nodes, spleen, and Peyer’s patches—which develop during embryogenesis at predetermined locations—TLS form postnatally in response to persistent inflammatory signals. They are considered inducible lymphoid organs that recapitulate many features of their secondary counterparts, including compartmentalized T cell and B cell zones, follicular dendritic cell networks, high endothelial venules, and functional germinal centers.

In the context of T1D, TLS have been observed within the pancreatic parenchyma, particularly in the periductal and peri-islet regions, as well as within fibrotic areas. Histological analyses of pancreas specimens from organ donors with T1D have revealed that approximately 40–60% of cases harbor detectable TLS, often in close association with residual islets. These structures vary in size and maturity, ranging from loose lymphoid aggregates to fully organized follicle-like formations with clear B cell zones and active germinal centers. The presence of TLS correlates with a more destructive insulitis profile, including extensive beta cell loss and islet inflammation. For a comprehensive review of TLS formation and function across autoimmune diseases, readers are directed to a key Nature Reviews Immunology article.

Structural Hallmarks of TLS

Fully developed TLS are characterized by several distinct components:

  • B cell follicles containing follicular dendritic cells (FDCs) that present unprocessed antigens and support B cell survival, proliferation, and affinity maturation.
  • T cell zones populated by CD4+ and CD8+ T cells, along with dendritic cells (DCs) that enable antigen presentation and T cell activation.
  • High endothelial venules (HEVs) that facilitate the entry of naive and central memory lymphocytes from the circulation into the lymphoid microenvironment.
  • Lymphatic vessels that drain antigens and cellular products to draining lymph nodes.
  • Stromal cells such as fibroblasts and podoplanin-expressing cells that provide structural support and produce chemokines that organize the structure.

These elements create a self-sustaining niche where immune cells can interact locally, bypassing the reliance on distant lymph nodes. In T1D, this local activation is thought to be a driving force behind the chronicity of the autoimmune attack.

The Role of TLS in T1D Autoimmunity

The discovery of TLS in T1D pancreas samples has raised critical questions about their functional contribution to disease. Do TLS simply reflect the long-term inflammatory milieu, or are they active participants in beta cell destruction? Accumulating evidence supports the latter. TLS in T1D are not static structures; they are dynamic sites of immune activation where autoreactive lymphocytes are generated and armed to destroy insulin-producing cells.

TLS as Local Hubs for Autoantibody Production

One of the hallmarks of T1D is the presence of autoantibodies directed against islet antigens, including insulin, glutamic acid decarboxylase (GAD65), islet antigen-2 (IA-2), and zinc transporter 8 (ZnT8). While these autoantibodies are produced by plasma cells in the bone marrow and lymphoid organs, TLS within the pancreas can serve as local centers for B cell activation and differentiation. Germinal centers within pancreatic TLS support class switching, affinity maturation, and somatic hypermutation of B cell receptors. Studies using single-cell sequencing and repertoire analysis have shown that B cells isolated from pancreatic TLS express highly mutated, clonally expanded antibodies specific to islet autoantigens. This local production of autoantibodies may not only contribute to the humoral attack against beta cells but also facilitate antigen presentation to T cells via internalization and processing of immune complexes. Research published in Diabetes has demonstrated that the presence of germinal centers in pancreatic TLS is linked to a more aggressive disease course and earlier onset.

T Cell Activation and Effector Function

CD4+ and CD8+ T cells are the primary effectors of beta cell destruction. Within TLS, dendritic cells and macrophages capture beta cell antigens released from dying cells and present them via MHC molecules to T cells. This local presentation reinforces the activation of autoreactive T cells and provides essential costimulatory signals. The organized microenvironment of TLS ensures that T cells receive sustained stimulation, promoting their proliferation and differentiation into cytotoxic effectors. Furthermore, TLS can support the generation of tissue-resident memory T cells, which may persist in the pancreas even after systemic immunosuppression, contributing to disease recurrence after islet transplantation. A study in the Journal of Clinical Investigation highlighted that CD8+ T cells within pancreatic TLS exhibit a highly activated, terminally differentiated phenotype, correlating with insulitis severity.

Cytokine and Chemokine Networks Sustaining TLS

The formation and maintenance of TLS depend on a complex network of chemokines, cytokines, and adhesion molecules. Lymphotoxin alpha1 beta2 (LTα1β2) expressed by activated lymphocytes binds to lymphotoxin beta receptor (LTβR) on stromal cells, inducing the expression of chemokines such as CXCL13, CCL19, CCL21, and CXCL12. These chemokines orchestrate the recruitment and compartmentalization of B cells and T cells. In the T1D pancreas, local elevation of these factors creates a permissive environment for TLS formation. The cytokine BAFF (BLyS) supports B cell survival and is overexpressed in the islet environment. Blockade of BAFF and LTβR signaling in animal models reduces TLS formation and attenuates autoimmune diabetes, indicating that these pathways are actionable therapeutic targets. Translational research in Cell Reports Medicine has demonstrated that disrupting TLS through biologic agents can reverse established diabetes in NOD mice, a model of T1D.

Evidence from Human Pancreas Studies

Critical insights into TLS in T1D have come from the Network for Pancreatic Organ Donors with Diabetes (nPOD) program, which collects and distributes human pancreas tissues. Using multiplex immunohistochemistry and gene expression profiling, nPOD-affiliated researchers have mapped the spatial organization of immune cells in T1D pancreata. Their work shows that TLS are predominantly found in donors with long-standing T1D, but they can also appear in recent-onset cases. Interestingly, TLS are often enriched near remnants of insulin-positive beta cells, suggesting a role in the ongoing immune response against residual self-antigens. These findings have been summarized in a comprehensive review available through PubMed.

Implications for Cure Research

The recognition that TLS are not merely epiphenomena but rather functional units driving autoimmunity has profound implications for T1D therapy. Current treatments, such as insulin replacement and immunomodulatory agents (e.g., teplizumab), address systemic immune dysregulation but do not specifically target the localized inflammatory hubs that sustain beta cell destruction. Approaches that disrupt TLS formation, eliminate existing TLS, or reprogram their immune activity could offer a more precise strategy to induce long-term tolerance.

Potential Therapeutic Strategies Targeting TLS

Several strategies are under investigation, both in preclinical models and early clinical trials.

  • Inhibition of TLS neogenesis: Blocking the LTβR pathway or neutralizing the chemokine CXCL13 can prevent the formation of new TLS. Small molecule inhibitors and monoclonal antibodies targeting these molecules have shown promise in mouse models of T1D and other autoimmune diseases.
  • Disruption of germinal center reactions: Agents that inhibit inducible costimulator (ICOS) signaling or CD40-CD40L interactions can shut down T cell help to B cells within TLS, reducing autoantibody production and curtailing the generation of memory B cells.
  • Depletion of specific immune subsets: Anti-CD20 antibodies (rituximab) deplete B cells and can disrupt TLS structure. While clinical trials in T1D have shown only modest preservation of C-peptide, combination approaches targeting both B cells and T cells might yield greater efficacy.
  • Reprogramming the local microenvironment: Fostering the development of regulatory T cells (Tregs) within TLS may convert these structures from pro-inflammatory to tolerogenic. Local delivery of low-dose IL-2 or adoptive transfer of Tregs could tip the balance toward immune regulation. Early-phase trials using low-dose IL-2 show safety and expansion of Tregs, though effects on TLS are not yet studied.
  • Targeting the stroma: Pancreatic fibroblasts and pericytes support TLS. Drugs that inhibit fibroblast activation or disrupt extracellular matrix remodeling could undercut the structural foundation of these structures.
  • Combination with antigen-specific immunotherapy: Co-administration of islet antigen coupled with immune-modulating nanoparticles or peptide therapy may re-educate autoreactive lymphocytes locally. TLS provide a concentrated arena where such interventions could have maximal impact by shifting the balance from effector to regulatory responses.

Challenges and Considerations

While targeting TLS offers an exciting frontier, several challenges remain. First, the timing of intervention is critical. TLS may be established early in the disease process and become resistant to disruption over time. Early detection of TLS formation, potentially through imaging with labeled antibodies or circulating biomarkers, could identify patients who would benefit most from anti-TLS therapy. Second, TLS may also have beneficial roles in infection control and tumor immunosurveillance. Systemic blockade of TLS formation could impair immune responses to pathogens or promote cancer development, especially in the pancreas where TLS have been associated with a better prognosis in pancreatic ductal adenocarcinoma. Thus, tissue-specific or localized approaches are needed. Third, human TLS exhibit considerable heterogeneity in their cellular composition, maturity, and function. A one-size-fits-all approach may not work; precision medicine strategies that tailor interventions to the TLS phenotype of each patient may be necessary.

Future Directions and Unanswered Questions

To move TLS-targeted therapies forward, the field must address fundamental gaps in knowledge. How do TLS originate in the pancreas? What triggers the initial switch from diffuse insulitis to organized lymphoid aggregates? Are there specific viral triggers that promote TLS formation? Does the gut microbiome influence the pancreatic TLS niche? Advances in spatial transcriptomics, proteomics, and live imaging will help dissect these questions. Organoid and microfluidic models of the T1D pancreas may allow real-time observation of TLS assembly and disassembly. Moreover, the development of humanized mouse models reconstituted with T1D patient immune cells could facilitate screening of anti-TLS agents in a more relevant system.

In parallel, large-scale clinical cohorts should incorporate systematic assessment of TLS in biopsy or surgical specimens. The correlation of TLS presence with clinical outcomes such as residual C-peptide, glycemic variability, and microvascular complications will help validate TLS as a relevant therapeutic target. Collaborative initiatives like nPOD and the JDRF-funded T1D research networks are already collecting longitudinal data, and their tissue repositories are invaluable resources.

Conclusion

Tertiary lymphoid structures represent a paradigm shift in our understanding of T1D immunopathology. Far from passive bystanders, these organized immune aggregates function as local command centers that amplify and sustain the autoimmune attack on beta cells. Their presence in the pancreas is associated with a more aggressive disease course, and the mechanisms by which they promote autoimmunity—from local autoantibody production to T cell activation—are becoming clearer. The therapeutic implications are substantial: TLS may provide a target-rich environment for interventions that can halt disease progression, protect residual beta cell mass, and possibly restore insulin secretion. As research unveils the molecular signals that drive TLS formation and maintenance, and as clinical tools for monitoring TLS in real time evolve, the prospect of translating this knowledge into durable cures for T1D moves closer. The path forward will require interdisciplinary collaboration, rigorous preclinical testing, and cautious clinical evaluation, but the promise of targeting these ectopic lymphoid structures offers renewed hope for millions living with T1D.